ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PROK vs ALLO // RSI-14 & 200D SMA MOMENTUM

ProKidney Corp. (Class A) (NASDAQ) VS. Allogene Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PROK 2 — ALLO 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PROK
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PROK VS. ALLO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PROK ALLO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 ALLO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 36.4 29.3 +7.07 PROK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $444.4M $431.9M $12.6M PROK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PROK REV ALLO REV PROK GROSS % ALLO GROSS % PROK FCF ALLO FCF
FY 2025 $0 $0 — — -$135.3M -$149.6M
FY 2024 $0 $22.0K — — -$155.9M -$201.0M
FY 2023 $0 $95.0K — — -$90.1M -$237.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PROK // BETA —
ALLO // BETA —